Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

We do know that PK-PD modeling for Brilacidin was highly predictive of the actual Phase 2b results and though PK-PD modeling has been used extensively for antibiotics, it's not a stretch to think that it will be used (with limitations) for anti-cancer agents.

I agree that Kevetrin is a completely different beast and much more complicated in terms of modeling. With a very short half life (about 2 hours in humans) it is likely amenable to frequent infusions as you suggest. Actually, I'd be curious about achieving a steady state level of Kevetrin with continuous infusion. Minimize dosing side effects and keep serum levels in some as-yet determined therapeutic range.

(see post 100217 from 3 weeks ago)

I'm really looking forward to the next few weeks.